Bulletin of the Korean Chemical Society

Korean Chemical Society (대한화학회)
권호 표지
DOI QR코드

DOI QR Code

Detecting Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) and Inactivated TAFIa (TAFIai) in Normal and Hemophilia A Plasmas

  • Hulme, John P. (Kyungwon University, Department of Bionano Technology) ;
  • An, Seong Soo A. (Kyungwon University, Department of Bionano Technology)
  • Published : 2009.01.20
Download PDF
⟨ Previous Next ⟩

Abstract

Thrombin activatable fibrinolysis inhibitor (TAFI) also known as plasma procarboxypeptidase B or U is a 60 kD glycoprotein, which is the major modulator of fibrinolysis in plasma. TAFI is a proenzyme, which is activated by proteolytic cleavage to an active carboxypeptidase B-like enzyme (TAFIa, 35.8 kD) by thrombin/thrombomodulin and plasmin. Modulation of fibrinolysis occurs when TAFIa enzymatically removes C-terminal lysine residues of partially degraded fibrin, thereby inhibiting the stimulation of tissue plasminogen activator (t-PA) modulated plasminogen activation. TAFIa undergoes a rapid conformational change at $37{^{\circ}C}$ to an inactive isoform called TAFIai. Potato tuber carboxypetidase inhibitor (PTCI) was shown to specifically bind to TAFIa as well as TAFIai. In this study, a novel immunoassay TAFIa/ai ELISA was used for quantitation of the two TAFI activation isoforms TAFIa and TAFIai. The ELISA utilizes PTCI as the capture agent and a double antibody sandwich technique for the detection. Low levels of TAFIa/ai antigen levels were detected in normal plasma and elevated levels were found in hemophilia A plasmas. TAFIa/ai antigen represents a novel marker to monitor fibrinolysis and TAFIa/ai ELISA may be a valuable assay for studying the role of TAFI in normal hemostasis and in pathological conditions.

Keywords

References

  1. Redlitz, A.; Tan, A. K.; Eaton, D. L.; Plow, E. F. J. Clin. Invest. 1995, 96, 2534 https://doi.org/10.1172/JCI118315
  2. Bajzar, L.; Manuel, R.; Neisheim, M. E. J. Biol. Chem. 1995, 270, 1477
  3. Bajzar, L.; Morser, J.; Neisheim, M. E. J. Biol. Chem. 1996, 271, 16603 https://doi.org/10.1074/jbc.271.28.16603
  4. Sakharov, D. V.; Plow, E. F.; Rijken, D. C. J. Biol. Chem. 1997, 272, 14477 https://doi.org/10.1074/jbc.272.22.14477
  5. Wang, W.; Boffa, M. B.; Bajzar, L.; Walker, J. B.; Neisheim, M. E. J. Biol. Chem. 1998, 273, 27176 https://doi.org/10.1074/jbc.273.42.27176
  6. Hendriks, D.; Wang, W.; Scharpe, S.; Lommaert, M. P.; van Sande, M. Biochim. Biophys. Acta 1990, 1034, 86 https://doi.org/10.1016/0304-4165(90)90157-R
  7. Marx, P. F.; Dawson, P. E.; Bouma, B. N.; Meijers, J. C. Biochemistry 2002, 41, 6688 https://doi.org/10.1021/bi015982e
  8. Marx, P. F.; Hackeng, T. M.; Dawson, P. E.; Griffin, J. H.; Meijers, J. C.; Bouma, B. N. J. Biol. Chem. 2000, 275, 12410 https://doi.org/10.1074/jbc.275.17.12410
  9. Franco, R. F.; Fagundes, M. G.; Meijers, J. C.; Reitsma, P. H.; Lourenco, D.; Morelli, V.; Maffei, F. H.; Ferrari, I. C.; Piccinato, C. E.; Silva, W. A. Jr.; Zago, M. A. Haematologica. 2001, 86, 510
  10. Henry, M.; Aubert, H.; Morange, P. E.; Nanni, I.; Alessi, M. C.; Tiret, L.; Juhan-Vague, I. Blood 2001, 97, 2053 https://doi.org/10.1182/blood.V97.7.2053
  11. Kostka, H.; Kuhlisch, E.; Schellong, S.; Siegert, G. Clin Lab. 2003, 49, 645
  12. Stromqvist, M.; Schatteman, K.; Leurs, J.; Verkerk, R.; Andersson, J. O.; Johansson, T.; Scharpe, S.; Hendriks, D. Thromb Haemost. 2001, 85, 12
  13. Van Thiel, D. H.; George, M.; Fareed, J. Thromb Haemost. 2001, 85, 667
  14. Meijers, J. C.; Oudijk, E. J. D.; Mosnier, L. O.; Bos, R.; Bouma, B. N.; Nieuwenhuis, H. K.; Fijnheer, R. Br. J. Haematol. 2000, 108, 518 https://doi.org/10.1046/j.1365-2141.2000.01890.x
  15. Watanabe, R.; Wada, H.; Watanabe, Y.; Sakakura, M.; Nakasaki, T.; Mori, Y.; Nishikawa, M.; Gabazza, E. C.; Nobori, T.; Shiku, H. Thromb Res. 2001, 104, 1 https://doi.org/10.1016/S0049-3848(01)00331-0
  16. Silveira, A.; Schatteman, K.; Goossens, F.; Moor, E.; Scharpe, S.; Stromqvist, M.; Hendriks, D.; Hamsten, A. Thromb Haemost. 2000, 84, 364
  17. van Tilburg, N. H.; Rosendaal, F. R.; Bertina, R. M. Blood 2000, 95, 2855
  18. Schatteman, K. A.; Goossens, F. J; Leurs, J.; Kasahara, Y.; Scharpe, S. S.; Hendriks, D. F. Clin. Chem. Lab Med. 2001, 39, 806 https://doi.org/10.1515/CCLM.2001.133
  19. Schneider, M.; Boffa, M.; Stewart, R.; Rahman, M.; Koschinsky, M.; Nesheim, M. J. Biol. Chem. 2002, 277, 1021 https://doi.org/10.1074/jbc.M104444200
  20. Gils, A.; Alessi, M. C.; Brouwers, E.; Peeters, M.; Marx, P.; Leurs, J.; Bouma, B.; Hendriks, D.; Juhan-Vague, I.; Declerck, P. J. Arterioscler Thromb Vasc Biol. 2003, 23, 1122 https://doi.org/10.1161/01.ATV.0000074145.58172.BD
  21. Knoefler, R.; Ludwig, K.; Kostka, H.; Kuhlisch, E.; Siegert, G.; Suttorp, M. Semin Thromb Hemost. 2003, 29, 575 https://doi.org/10.1055/s-2004-815625
  22. Guimaraes, A. H.; van Tilburg, N. H.; Vos, H. L.; Bertina, R. M.; Rijken, D. C. Br. J. Haematol. 2004, 124, 659 https://doi.org/10.1111/j.1365-2141.2004.04824.x
  23. Tani, S.; Akatsu, H.; Ishikawa, Y.; Okada, N.; Okada, H. Microbiol Immunol. 2003, 47, 295 https://doi.org/10.1111/j.1348-0421.2003.tb03398.x
  24. Schatteman, K. A.; Goosens, F. J.; Scharpe, S. S.; Neels, H. M.; Hendriks, D. F. Clin. Chem. 1999, 45, 807
  25. Lwaleed, B. A.; Goyal, A.; Greenfield, R. S.; Cooper, A. J. Blood Coagul. Fibrinolysis 2007, 18, 449 https://doi.org/10.1097/MBC.0b013e328136c18a
  26. Grunewald, M.; Siegemund, A.; Grunewald, A.; Konegan, A.; Koksch, M.; Griesshammer, M. Haemophilia 2002, 8, 768 https://doi.org/10.1046/j.1365-2516.2002.00686.x
  27. Mosnier, L. O.; Lisman, T.; van den Berg, H. M.; Nieuwenhuis, H. K.; Meijers, J. C.; Bouma, B. N. Thromb Haemost. 2001, 86, 1035
  28. Neill, E. K.; Stewart, R. J.; Schneider, M. M.; Nesheim, M. E. Anal. Biochem. 2004, 330, 332 https://doi.org/10.1016/j.ab.2004.04.007
  29. Antovic, J.; Schulman, S.; Eelde, A.; Blomback, M. Haemophilia 2001, 7, 557 https://doi.org/10.1046/j.1365-2516.2001.00571.x
  30. Greenfield, R. S.; Antovic, J.; An, J.; Blombeck, M.; An, S. S. A. Proceedings of the 16th Int'l Congress Fibrinolysis and Proteolysis 2002; Abstr. S49

Cited by

  1. Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis vol.45, pp.4, 2010, https://doi.org/10.5045/kjh.2010.45.4.264
  2. Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis vol.17, pp.6, 2009, https://doi.org/10.1111/jth.14432
  3. Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery? vol.22, pp.2, 2021, https://doi.org/10.3390/ijms22020883
  4. Endogenous fibrinolysis inhibitors in acute coronary syndrome vol.10, pp.None, 2021, https://doi.org/10.1016/j.ahjo.2021.100058